Compare Abeona Therapeutics Inc (ABEO) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Plby Group Inc — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Plby Group Inc trades at $1.27 (market cap $162.94M). The key difference: Abeona Therapeutics Inc is far larger — about 2.6× Plby Group Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | PLBY | |
|---|---|---|
Market Cap | $421.19M | $162.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $2.71 |
52-Week Low | $4.17 | $1.11 |
Enterprise Value | $276.10M | $308.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
PLBY trades at $1.18, down 3.28% recently, with a bearish technical signal. The company reported Q2 2026 revenue growth and positive operating cash flow, with net income turning positive in 2026 after years of losses. Valuation ratios like P/E of 68 and P/S of 1.2 appear elevated relative to profitability. Recent news highlights inclusion in Russell indexes and leadership expansion.
The outlook is cautiously optimistic with improving fundamentals, but high debt and thin margins pose risks. Analyst consensus is strongly bullish with 75% buy ratings, yet the stock faces execution risks in licensing growth and competitive pressures in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
